Collaboration on the discovery and the development of new drug targets and candidates for CNS diseases

GENOPIA Biomedical LLC (GENOPIA), a biotechnology firm headquartered in Saarbücken, Germany and Ciphergen Biosystems, Inc. (Nasdaq: CIPH) in Fremont, CA, will collaborate on the discovery and the development of new drug targets and candidates for CNS diseases. GENOPIA Biomedical focuses on the development of novel drug candidates and uses advanced proteomics as its main drug discovery and high-throughput screening tool, while Ciphergen Biosystems is a world leader in the development of proteomics technology, most notably its SELDI (Surface-Enhanced Laser Desorption/Ionization) ProteinChip® technology. The close collaboration between GENOPIA and Ciphergen reflects the growing importance of proteomics in modern drug discovery. Plans include the joint development of highly customized ProteinChip® surfaces to meet GENOPIA ’s needs for its proprietary drug targets.

Drs. Bernhard Schu (CEO) and Helge Völkel (CSO) of GENOPIA , commented on the collaboration between the two companies: “Stroke is one of the most common neurological conditions, and represents one of the largest pharmaceutical markets in the 21st century. Scientists at GENOPIA have identified proteins that play key roles in the cellular response to hypoxia and hypoxia-reperfusion injury, key components of stroke. In a mouse model of stroke, we were able to demonstrate the importance of these target proteins. The use of specially adapted, state-of-the-art Ciphergen ProteinChip® technology will greatly accelerate our drug discovery process, and also allow us to shorten the time to further characterize our already identified drug candidates.”

Drs. Bernhard Schu and Helge Voelkel continued “The objective is to accelerate protein biology research, with the same ease and success in which genomic and molecular biology research is done today. We envision new products that combine the expertise of both companies to create rapid ‘gene to protein’ transcription, translation, and protein purification capabilities at various scales, tagged or tag-free, as well as advanced ‘on-chip’ molecular-interaction and cellular assay platforms that further enable functional genomics.”

This press release contains statements on planned developments. The release reflects the intentions and opinions of GENOPIA Biomedical and Ciphergen, Inc., at the time of the release. This release is not be construed as a binding statement by either company.

Media Contact

GENOPIA

Alle Nachrichten aus der Kategorie: Life Sciences

Articles and reports from the Life Sciences area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Zurück zur Startseite

Kommentare (0)

Schreib Kommentar

Neueste Beiträge

Scientists achieve higher precision weak force measurement between protons, neutrons

Through a one-of-a-kind experiment at the Department of Energy’s Oak Ridge National Laboratory, nuclear physicists have precisely measured the weak interaction between protons and neutrons. The result quantifies the weak…

High-performance single-atom catalysts for high-temperature fuel cells

Individual Pt atoms participate in catalytic reaction to faciitate the electrode process by up to 10 times. Single-atom Pt catalysts are stable at 700 degrees Celsius and expected to stimulate…

New method allows precise gene control by light

A novel optical switch makes it possible to precisely control the lifespan of genetic “copies”. These are used by the cell as building instructions for the production of proteins. The…

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close